@article{ref1,
title="Reduced risk of suicidal behaviors associated with the treatment of hidradenitis suppurativa with tumor necrosis factor (TNF) alpha antagonists: results from the US FDA Adverse Events Reporting System (FAERS) pharmacovigilance database",
journal="Journal of the European Academy of Dermatology and Venereology",
year="2020",
author="Gupta, M. A. and Sheridan, A. D. and Gupta, A. K.",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, recurrent condition that presents as painful, suppurating lesions in the apocrine gland-bearing skin regions. HS has been associated with increased suicidal behaviors (SB), independent of any treatment. TNF-alpha antagonists are used to treat moderate-to-severe HS and have also been associated with SB, a factor that could confound the decision to use the TNF-α antagonists in the moderately-to-severely affected HS patients, who may already be experiencing increased SB risk. <br><br>OBJECTIVES: To determine presence or absence of a safety signal for SB when HS is treated with TNF-α antagonists. <br><br>METHODS: We calculated the Reporting Odds Ratios (ROR) with 95%CI of SB associated with treatment for HS with TNF-α antagonists versus the reference group of all other treatments for HS in the US Food and Drug Administration pharmacovigilance database from January 1, 2004 -March 31, 2019. A second analysis excluded isotretinoin (which has been used to treat HS and has also been associated with SB) from the reference group. <br><br>RESULTS: There was a signal for decreased risk of SB with TNF-α antagonists (ROR=0.1959, 95% CI 0.1247-0.3079; z=7.071, p<0.0001] versus all other HS treatments; the ROR did not change significantly after isotretinoin was excluded from the reference group. <br><br>CONCLUSIONS: Treatment of HS with TNF-α antagonists is associated with a decreased risk of SB.<br><br>© 2020 European Academy of Dermatology and Venereology.<p /> <p>Language: en</p>",
language="en",
issn="0926-9959",
doi="10.1111/jdv.16224",
url="http://dx.doi.org/10.1111/jdv.16224"
}